Millrace Asset Group’s Ligand Pharmaceuticals LGND Stock Holding History

Millrace Asset Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-15,690	Closed	-$933K	–	84
2020 Q3	$933K	Sell	15,690 -8,762	-36%	-$598K	0.75%	64
2020 Q2	$1.71M	Buy	+24,452	New	+$1.55M	1.74%	20
2019 Q3	–	Sell	-21,915	Closed	-$1.56M	–	70
2019 Q2	$1.56M	Sell	21,915 -6,939	-24%	-$511K	1.61%	25
2019 Q1	$2.26M	Buy	+28,854	New	+$2.19M	1.91%	19

Other funds holding LGND

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Millrace Asset Group's LGND Position: Q4 2020 in Review

Millrace Asset Group sold out of Ligand Pharmaceuticals (LGND) in Q4 2020, closing a stake of 15,690 shares — an estimated $933K sold.

Millrace Asset Group first reported a position in LGND in Q1 2019 and held it in 4 quarters. The position peaked at $2.26M in Q1 2019. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

Millrace Asset Group reported no remaining Ligand Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Millrace Asset Group sold 15,690 Ligand Pharmaceuticals shares in Q4 2020, an estimated $933K.
Millrace Asset Group first reported a position in Ligand Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Millrace Asset Group's Ligand Pharmaceuticals position peaked at $2.26M in Q1 2019.
242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on Millrace Asset Group's 13F filing for Q4 2020, filed 11 Feb 2021.